1 / 27

Chapter 10: Bipolar Disorders

Chapter 10: Bipolar Disorders. David J. Miklowitz Sheri L. Johnson. Diagnosis: Diagnostic Features. Insomnia or hypersomnia Psychomotor agitation or retardation, Changes in weight or appetite Loss of energy Difficulty concentrating or making decisions Feelings of worthlessness or guilt

mardi
Download Presentation

Chapter 10: Bipolar Disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chapter 10:Bipolar Disorders David J. Miklowitz Sheri L. Johnson

  2. Diagnosis: Diagnostic Features • Insomnia or hypersomnia • Psychomotor agitation or retardation, • Changes in weight or appetite • Loss of energy • Difficulty concentrating or making decisions • Feelings of worthlessness or guilt • Suicidal ideation or behavior • Severe changes in mood, thinking, and behavior, from extreme highs to lows • Distinctive “episodes” lasting a few days to a year or more. • Depressive episode: ≥ Five of the following for 2 weeks or longer with significant distress and/or decline in functioning • Intense sadness and/or loss of interest must be present

  3. Diagnosis: Manic and Hypomanic Episodes • Manic episode: Notably different elated, expansive, or irritable mood with ≥ 3 (≥ 4 if irritable) of the following lasting for at least 1 week and causing significant distress or impairment: • Inflated self-esteem (grandiosity) • Decreased need for sleep • Racing thoughts or flight of ideas • Rapid or pressured speech • Reckless and impulsive behavior • Enhanced energy • Increased goal-directed activity • Distractibility • Hypomanic episode: Same symptom criteria, but… • Shorter (4 days instead of 1 week) • Not severe enough to cause marked impairment in functioning (no psychotic features and no hospitalization)

  4. Diagnosis: Diagnostic Criteria • Bipolar I (BD-I) • Criteria met for at least 1 manic episode • Not better explained by a schizophrenia spectrum disorder (e.g., schizophrenia) • Bipolar II (BD-II) • Criteria met for at least one hypomanic episode and one depressive episode • Criteria never met for manic episode • Not better explained by schizophrenia spectrum disorder

  5. Diagnosis: Related Conditions • Bipolar disorder not elsewhere classified • Patients with brief and recurrent manic or hypomanic phases that fall short of the duration criteria • Cyclothymia • 2 or more years of switching between hypomanic and depressive symptoms that do not meet the full DSM-5 criteria for a hypomanic or a major depressive episode

  6. Diagnosis: Some Potential Specifiers • With mixed features: Features of depressive episode present during manic episode or vice versa • More debilitating course of illness, earlier onset, and greater comorbidity with anxiety and substance use disorders • Rapid cycling: Four or more episodes of depression, mania, or hypomania in 1 year • 10%–20% of cases, more common in bipolar II and women

  7. Diagnosis: Changes in DSM-5 • Increased activity is now a cardinal (Criterion A) symptom • Helps diagnose people who can describe behavior well but not internal experience • Mixed episode specifier no longer requires meeting full criteria for mania and depression simultaneously

  8. Diagnosis: Comorbid Disorders • Virtually all bipolar patients have a lifetime history of other psychiatric disorders • Anxiety disorders (62.9%) • ADHD and/or oppositional defiant disorder (44.8%) • Substance use disorders (36.8%) • In children, comorbidity of BD with ADHD is between 60% and 90%

  9. Symptoms: Presentation Differences • Patients with bipolar II disorder spend the majority of their ill weeks depressed, not hypomanic (ratio of 37 to 1) • Bipolar I ratio is about 3:1 • 80% of youths show irritability and grandiosity, whereas 70% have elated mood, decreased need for sleep, or racing thoughts • Less frequent symptoms: hypersexuality and psychotic symptoms

  10. Symptoms: Suicidality • Among those hospitalized for BD, 15x greater risk for completed suicide than the general population • 4x greater risk than patients with major depressive disorder • Risk factors: • Comorbid alcohol or substance abuse • Younger age • Recent illness onset • Male gender • Prior suicide attempts • Family history of suicide • Rapid cycling course • Social isolation • Anxious mood • Recent severe depression • “Impulsive aggression”

  11. Prognosis • Majority of patients with BD experience significant impairment in work, social, and family functioning during and after illness episodes • One third work full time outside of the home • More than half unable to work or work only in sheltered settings • Negative predictors: subsyndromal depressive symptoms following a manic episode and cognitive dysfunction • 1 in 10 BD-II patients eventually develop a full manic or mixed episode and are then diagnosed with BD-I

  12. Epidemiology • 1% meet lifetime criteria for BD-I; 1.1% for BD-II • 2.4% meet criteria for subthreshold BD; 4.2% cyclothymia • Mean age at onset • 18.4 years BD-I • 20.0 years BD-II • 21.9 years subthreshold BD • Between 50% and 67% of BD-I and BD-II have onset before age 18 • 15% and 28% before age 13 • In community studies, 25% to -33% of bipolar I patients have unipolar mania

  13. Etiology: Expressed Emotion • Expressed emotion attitudes (EE) - criticism, hostility, or emotional overinvolvement • Affective negativity (AE): Criticism, hostility, or guilt induction • BD patients who return home to high EE or AE families are at ~94% risk for relapse within 9 months • ~17% returning to low EE and AE families

  14. Etiology: Unipolar Depression Overlap • Predictors of recurrent and severe symptoms in both disorders include low social support, family EE, and neuroticism • Negative life events equally predictive of relapse • Heritability for unipolar depression and mania modestly correlated, but 71% of genetic liability to mania is distinct from depression • Variables that influence the course of unipolar depression also influence BD depression

  15. Etiology: Stress • BD patients with high levels of stressful life events are at 4.5x greater risk for relapse within 2 years • Number of prior episodes of illness does not interact with life events stress in predicting recurrences • Contrary to kindling model • Patients with severe early adversity (e.g., parental neglect or sexual/physical abuse) report less stress prior to illness recurrences and earlier age at onset • Supports stress sensitization model

  16. Etiology: Reward Sensitivity and Goal Setting • People with a history of mania describe themselves as more likely to react with strong emotions to reward cues (reward sensitive) • Elevated reward sensitivity predicts BD onset and a more severe course of mania among BD-I patients • Goal-attainment-type life events predict increases in manic symptoms but not depressive symptoms • Highly ambitious life goals/goal setting associated with more severe course of mania and onset of BD

  17. Etiology: Brain Systems • Abnormally strong activity in the dopaminergic pathways involved in reward sensitivity • Nucleus accumbens and the ventral tegmentum • Reduced connectivity between limbic (emotion-related) brain regions and prefrontal regions • May explain why patients with bipolar disorder have unstable mood and hyperreactivity to events • Diminished activity of the PFC might interfere with the ability to inhibit emotions and to conduct effective planning and goal pursuit

  18. Biological Etiology: Heritability • Genetic studies show bipolar disorder is among the most heritable of disorders. Heritability estimates from twin studies are as high as .85 to .93 • Risk of bipolar disorder among first-degree relatives between 5% and 12% • Risk of all forms of mood disorder between 20% and 25% • Monozygotic twins of BD-I patients are at an increased risk for schizophrenia (13.6%) and mania (36.4%)

  19. Biological Etiology: Neurotransmitters • Research emphasis has shifted from absolute levels of neurotransmitters to the overall functioning of systems • Neural plasticity and disturbed intracellular signaling cascades rather than the amount of dopamine or serotonin • Dopamine theory: Dopamine function is enhanced during mania and diminished during depression • Dopamine precursors, such as l-dopa, can trigger mania • Mood disorders generally associated with decreased serotonin receptor sensitivity

  20. Treatment- Lithium Medication and Nonadherence • Lithium: A mood stabilizer • 60% to 70% improve on lithium during a manic episode • Also helps prevent relapse • Significant side effects: sedation, weight gain, tremors of the hands, stomach irritation, thirst, and kidney problems • 40% to 60% of patients are fully or partially nonadherent with stabilizer regimens in the year after a manic episode • In community, patients take lithium for an average of only 2 to 3 months • Rapid discontinuation of lithium places patients at higher risk for recurrence and suicide

  21. Treatment: Pharmacological: Anticonvulsants/Mood Stabilizers • Divalproex sodium (Depakote) is as effective as lithium in controlling manic episodes • Generally more benign side effects: stomach pain, nausea, weight gain, elevated liver enzymes, and lowering of blood platelet counts • Combination therapy and lithium alone both more effective than divalproex alone in preventing relapse • Other anticonvulsants/mood stabilizers • Carbamazepine (Tegretol), lamotrigine (Lamictal), and oxcarbazepine (Trileptal)

  22. Treatment: Pharmacological: Suicide Prevention • Patients treated with lithium, antipsychotics, or antidepressants (especially in combination regimens) have lower suicide rate • Lithium was more effective than divalproex sodium in reducing suicide attempts and completions

  23. Treatment: Pharmacological Other Medications • Olanzapine (atypical antipsychotic medication) • Prevention of recurrences of mania or mixed episodes is as good or better than lithium or divalproex • Concerns about side effects: weight gain and metabolic syndrome • Quetiapine, risperidone, aripiprazole, and ziprasidone are alternatives with lower side-effect risk • Not clear that combinations of SSRI and mood stabilizer are effective for treating BD depression • Risk of more frequent mood cycles

  24. Treatment: Group Psychotherapy • Structured group psychoeducation • Education about BD, relapse, and importance of medication • After 2 years, relapse is 67% vs. 92% in controls, and fewer hospitalized • More likely to maintain lithium levels within the therapeutic range • Group treatment is most cost-effective form of psychotherapy • Integrated CBT group treatment for bipolar adults with comorbid substance dependence • Focuses on the overlap between the cognitions and behaviors of both conditions during recovery and relapse • About half as many days of substance use as those receiving only drug counseling

  25. Treatment: Individual Psychotherapy • Interpersonal and Social-Rhythm Therapy (IPSRT) • Stabilize social rhythms and resolve interpersonal problems that precede episodes • Track daily routines and sleep/wake cycles and identify events that change those routines • Delays recurrence if begun during acute phase • Individual psychoeducational treatment and medication • 7 to 12 sessions • 30% reduction in mania relapse, longer time before relapse, and enhanced social functioning

  26. Treatment: Family Focused Treatment (FFT) • Group therapy with patient and family • Goal: Reduce high EE attitudes and enhance communication • Psychoeducation about BD and develop relapse prevention drill • Communication-enhancement training • Problem-solving skills training • Efficacy vs. standard care over 2 years • Less likely to relapse (17% vs. 52%) • Greater improvements over time in depression, manic symptoms, and better adherence to medications

  27. Treatment: Psychotherapy Efficacy Comparison (STEP-BD) • 30 sessions of IPSRT, FFT, or CBT over 9 months for BD-I and BD-II starting in depressed episode • Control condition was three sessions of psychoeducation; medication prescribed in all conditions • Treatment conditions more likely to recover rapidly from depression, remain well, better overall functioning, relationship functioning, and life satisfaction • One-year rates of recovery same across intensive therapy groups

More Related